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Abstract
Background: This study was conducted to evaluate drug resistance amongst bacteremic isolates of
febrile neutropenic patients with particular emphasis on emergence of carbapenem resistant Gram
negative bacteria and vancomycin resistant Enterococcus species.
Methods: A descriptive study was performed by reviewing the blood culture reports from febrile
neutropenic patients during the two study periods i.e., 1999–00 and 2001–06. Blood cultures were
performed using BACTEC 9240 automated system. Isolates were identified and antibiotic sensitivities
were done using standard microbiological procedures.
Results: Seven twenty six febrile neutropenic patients were admitted during the study period. A total of
5840 blood cultures were received, off these 1048 (18%) were culture positive. Amongst these, 557 (53%)
grew Gram positive bacteria, 442 (42%) grew Gram negative bacteria, 43 (4%) fungi and 6 (1%) anaerobes.
Sixty (5.7%) out of 1048 positive blood cultures were polymicrobial. In the Gram negative bacteria,
Enterobacteriaceae was the predominant group; E. coli was the most frequently isolated organism in both
study periods. Amongst non- Enterobacteriaceae group, Pseudomonas aeruginosa was the commonest
organism isolated during first study period followed by Acinetobacter spp. However, during the second
period Acinetobacter species was the most frequent pathogen.
Enterobacteriaceae group showed higher statistically significant resistance in the second study period
against ceftriaxone, quinolone and piperacillin/tazobactam, whilst no resistance observed against
imipenem/meropenem. The susceptibility pattern of Acinetobacter species shifted from sensitive to highly
resistant one with significant p values against ceftriaxone, quinolone, piperacillin/tazobactam and
imipenem/meropenem. Amongst Gram positive bacteria, MRSA isolation rate remained static, vancomycin
resistant Enterococcus species emerged in second study period while no Staphylococcus species resistant to
vancomycin was noted.
Conclusion:  This rising trend of highly resistant organisms stresses the increasing importance of
continuous surveillance system and stewardship of antibiotics as strategies in the overall management of
patients with febrile neutropenia.
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Background
Febrile neutropenia is associated with high mortality rate
therefore institution of timely and appropriate empirical
antibiotic therapy is absolutely essential [1,2]. Globally
significant change in the spectrum of organisms and their
susceptibility pattern is observed in febrile neutropenic
over the past few decades. Staphylococcus aureus was the
most frequent isolate from these patients in 1950s and
early 1960s and was later replaced by Gram-negative
bacilli including Escherichia coli,  Klebsiella  species and
Pseudomonas aeruginosa [3]. However since 1980s, resur-
gence of Gram-positive organisms in this population is
evident [4]. Recently non-fermenter Gram negative rods
such as Acinetobacter species have emerged as pathogens in
these patients [5]. Additionally use of broad spectrum
antibiotics has resulted in emergence of multi drug resist-
ant Gram negative and gram positive bacteria. Therefore,
the choice of empiric therapy should vary according to
locally prevalent isolates and their resistance patterns.
Currently, use of carbapenem as an empirical mono-
therapy for febrile neutropenic patient is justified in most
centers due to growing resistance against other beta
lactam antibiotics [6,7]. Similarly empirical use of vanco-
mycin for suspected penicillin and methicillin resistant
Gram positive bacterial infection is recommended [2].
Emergence and spread of carbapenem resistant Gram neg-
ative rods is a great concern, especially in a resource lim-
ited country such as Pakistan, where treatment
alternatives are either unavailable or expensive/toxic with
poor outcome [8]. The Aga Khan University is a major ter-
tiary care hospital in Pakistan that caters a large popula-
tion of severely immuno-suppressed patients. The
hospital has a hematology-oncology unit along with a
bone marrow transplant unit. Recent reports from our
center have documented emergence and spread of carbap-
enem resistance among multi-resistant non enterobacte-
riaceae including Acinetobacter  species and Pseudomonas
aeruginosa [9,10]. In addition, our hospital infection con-
trol surveillance committee also reported rising trend of
carbapenem resistance in Acinetobacter species and Pseu-
domonas aeruginosa, beginning from the year 2001. This
has raised the concern about possibility of emergence of
these pathogens in febrile neutropenic patients. Similarly
rising trend of methicillin resistant Staphylococcus aureus
and emergence of vancomycin resistant enterococci
amongst the hospitalized patients are of great concern
[11]. We therefore conducted a study to evaluate drug
resistance in bacteremic isolates of febrile neutropenic
patients with particular emphasis on emergence of car-
bapenem resistant gram negative bacteria. In addition to
that we tried to evaluate the frequency of methicillin
resistant Staphylococcus aureus and vancomycin resistance
Enterococcus species isolated from blood cultures in these
patients.
Methods
This study was conducted in the department of Pathology
and Microbiology, Aga Khan University Karachi, Pakistan.
Medical records and blood cultures of febrile neutropenic
patients, admitted from year 1999 to 2006 were reviewed.
To evaluate the changing pattern and increasing antimi-
crobial resistance of microorganisms in febrile neutro-
penic patients, we divided the study duration in two
periods, the first period comprised of January 1999 to
December 2000 while the second period was from Janu-
ary 2001 to December 2006.
Neutropenia was defined as neutrophil counts of 500 or
1000 with predicted decline to 500. Fever was defined as
oral temperature of 38°C or above for at least one hour
[1]. Blood cultures received from all febrile neutropenic
patients between this six and half year study period were
included in the study. To avoid error the duplicates were
removed (we considered duplicate if same isolate grew
more than once during that admission).
Blood cultures were performed using BACTEC 9240 auto-
mated system. A set of aerobic and anaerobic bottles con-
taining brain heart infusion and thioglycolate broth
respectively, were used for cultures. Negative blood cul-
ture bottles were incubated for seven days before being
reporting negative. Blood culture isolates were identified
using standard microbiological procedure and further
confirmation was done using commercially available API
strips [12]. Antibiotic sensitivities of all isolates except
non enterobacteriaceae were carried out using Kirby Bauer
method [13]. Sensitivity testing for non enterobacte-
riaceae was done using agar dilution method as recom-
mended by CLSI [13].
Statistical analysis: Descriptive analysis was done by cal-
culating frequency and percentages. In order to evaluate
the difference in the sensitivity patterns of both gram neg-
ative and gram positive organisms during the two halves
of the study period, chi square test or Fisher exact where
appropriate was performed with a significance level of
5%.
Results
During the study period (1999–2006), 726 febrile neutro-
penic patients were admitted. We reviewed medical
records of randomly selected 134/726 (18.4%) patients.
Amongst these, 49% belonged to hematological malig-
nancy, 44% had solid organ cancer while in 7% of cases
diagnosis was not established. Chest was the commonest
site of infection (21%), followed by skin & soft tissue
(12.6%), gastroenteritis (11%), mucositis (8.2%), porta
cath (8.2%) and others (9.7%). No obvious focus of infec-
tion was found in 25.3% cases.BMC Infectious Diseases 2008, 8:80 http://www.biomedcentral.com/1471-2334/8/80
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A total of 5840 blood cultures were received, off these
1048 (18%) were culture positive. Amongst these, 557
(53%) grew Gram positive bacteria, 442 (42%) grew
Gram negative bacteria, 43 (4%) fungi and 6 (1%) anaer-
obes. Sixty out of 1048 (5.7%) positive blood cultures
were polymicrobial. Amongst these 93.4% were positive
for two organisms, 5% for three and 1.6% for four organ-
isms. Increasing trend was observed in the isolation rate of
gram positive bacteria i.e. from 50% in first study period
to 54% in the second one. A little drop in isolation rate of
gram negative bacteria was noted i.e. from 43% to 41%.
No statistically significant difference for the isolation rate
of Staphylococci, Streptococci and other gram positive bacte-
ria was found between the two study periods, as shown in
Table 1.
Amongst the gram negative bacteria, Enterobacteriaceae
remained the predominant group, comprising of 65%
and 64% of total gram negative bacteria in the first and
second study period respectively as shown in Table 2. E.
coli was the most frequently isolated organism in both
study periods. The isolation frequency of non enterobac-
teriaceae was found to be static in both study periods i.e.
25–30% of the total gram negative organisms. Amongst
this group, Pseudomonas aeruginosa was the commonest
organism isolated during first study period followed by
Acinetobacter spp. However, during the second period Aci-
netobacter  species was the most frequent pathogen.
Another important finding was the emergence of Stenotro-
phomonas maltophilia, Aeromonas species and Achromo-
bacter species during the second study period.
A significant rise in drug resistant isolates was noted in the
second study period. This increase was identified for all
gram negative bacteria including Enterobacteriaceae, Pseu-
domonas aeruginosa, other Pseudomonas  species and Aci-
netobacter species as shown in Table 3a &3b. Amongst the
Enterobacteriaceae, statistically significant resistance
appeared in the second study period against ceftriaxone (p
= 0.001), ciprofloxacin/ofloxacin (p = 0.003) and pipera-
cillin/tazobactam (p = 0.006). However no resistance
against imipenem/meropenem was detected in second
study period. Fifty four percent of Enterobacteriaceae were
ESBL positive during the second study period.
Similarly increased resistance in Pseudomonas aeruginosa
was noted against amikacin and ciprofloxacin/ofloxacin
during the second study period. However, this difference
was not statistically significant (p > 0.05). No resistance
against piperacillin/tazobactam and imipenem/mero-
penem was found during the first study half; however
resistance against both of these antibiotics (6%) appeared
in the second study period. The susceptibility pattern of
Acinetobacter species shifted from sensitive to highly resist-
ant one with significant p values against third generation
cephalosporin (p = 0.001), quinolone (p = 0.004), piper-
acillin/tazobactam (p = 0.003) and imipenem/mero-
penem (p = 0.003). During the second study period 37%
(49/134) of total non- enterobacteriaceae were found imi-
penem/meropenem resistant making a total of 14% (49/
352) imipenem resistance amongst all gram negative bac-
teria.
Among the gram positive bacteria isolation frequency of
methicillin resistant Staphylococcus aureus was not statisti-
cally significant (p = 0.524), however, vancomycin resist-
ant Enterococcus species emerged in second half of study as
shown in Table 4. No Staphylococcus species resistant to
vancomycin was isolated.
Discussion
Our study showed rising trend of carbapenem resistant
Gram negative and vancomycin resistant Gram positive
bacteria among bacteremic isolates of febrile neutropenic
Table 1: Gram positive bacteria isolated from blood cultures in two halves of study period.
(Period 1) Positive blood culture (Period II) Positive blood culture
Gram positive Bacteremic isolates n = 104 % n = 453 % P-value
Staphylococcus spp. 56 53.8 250 55.2 0.804
Staphylococcus aureus 14 13.5 43 9.5 0.228
Streptococcus spp. 6 5.8 25 5.5 0.920
Enterococcus spp. 7 6.7 23 5.1 0.501
Bacillus spp. 10 9.6 44 9.7 0.976
Micrococcus spp. 3 2.9 17 3.8 0.999 #
Streptococcus pneumoniae 2 1.9 16 3.5 0.548 #
Corynebacterium spp. 5 4.8 25 5.5 0.772
Streptococcus pyogenes 1 1.0 5 1.1 0.999 #
Nocardia spp. 0 0.0 1 0.2 0.999 #
Other Gram positive organism 0 0.0 4 0.9 0.999 #
p-values calculated by Chi square test otherwise indicated
# p-value calculated by Fisher exact testBMC Infectious Diseases 2008, 8:80 http://www.biomedcentral.com/1471-2334/8/80
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patients. The emergence of carbapenem resistant isolates
in our center is likely to be associated with change in anti-
biotic policies. The two study periods were chosen based
on difference in empirical antibiotic choice in our center.
During nineties third generation cephalosporin was the
empirical antibiotic choice for febrile neutropenic
patients at our institute [14]. However, rising trend of
resistance against this group of antibiotics was observed
among  Enterobacteriaceae  and  Pseudomonas aeruginosa
[15,16]. Prior to year 2000, there was limited availability
of piperacillin/tazobactam and imipenem. These agents
were introduced throughout the hospital in year 2000
[15].
Our study revealed no resistance to carbapenem and min-
imal resistance against piperacillin/tazobactam in Gram
negative isolates during the first study period. However,
rising trend of resistance against these agents was noted in
second period. This change was specific for non entero-
bacteriaceae group. These bacteria showed significant rise
in resistance against major antibiotics including third gen-
eration cephalosporin, quinolone, amikacin, piperacillin/
tazobactam and carbapenem. In contrast to this no resist-
ance against carbapenem was noted amongst Enterobacte-
riaceae group.
Another important finding was increased isolation rates
of Acinetobacter species. This organism was the sixth Gram
negative bacteria isolated during the first study period;
however it became the second most commonly isolated
gram negative bacteria during the second study period.
Moreover, carbapenem resistance in this bacterium was
significantly high (p = 0.003) during second study period,
indicating possible role of nosocomial transmission for
this rising trend. Finally, emergence of Gram negative
organism inherently resistant to carbapenem like Stenotro-
phomonas maltophilia during the second study period was
another area of concern, a finding consistent with other
reports [17]. Our findings are in contrast to other regional
reports, where carbapenem resistance in this population is
not observed [18,19].
The isolation rate of MRSA during the two study halves
was comparable (p = 0.524). The isolation rate of MRSA
(31%) was significantly high when compared with the
previous study done in 1991 which reported 100% sus-
ceptibility against cloxacillin [14]. Similar increase in iso-
lation rate of methicillin resistant Staphylococcus aureus
(MRSA) was also reported in another study from Taiwan
[20]. Moreover emergence of vancomycin resistant Entero-
coccus species (VRE) not only poses a therapeutic chal-
lenge for febrile neutropenic patients [21,22] but also
indirectly reflects irrational usage of vancomycin and poor
infection control practices. The increasing rates of antimi-
crobial resistance amongst both Gram-positive and Gram-
negative pathogens isolated from patients with neutrope-
nia are posturing new therapeutic challenges. These chal-
lenges are compounded by the fact that relatively few new
drugs are being developed, particularly those that treat
resistant Gram-negative organisms [22]. As these trends
are often associated with local treatment practices [22,23]
therefore, we suggest rational use of broad-spectrum anti-
biotics especially carbapenem and vancomycin to prevent
increasing resistance against them. In addition compro-
Table 2: Gram negative bacteria isolated from blood cultures in two halves of study period
(Period 1) Positive blood culture (Period II) Positive blood culture
Gram Positive Bacteremic Isolates n = 90 % n = 352 % P-value
E. coli 26 28.9 129 36.6 0.169
P. aeruginosa 15 16.7 34 9.7 0.059
Enterobacter spp. 12 13.3 30 8.5 0.165
Pseudomonas spp. 8 8.9 29 8.2 0.842
Klebsiella spp. 11 12.2 41 11.6 0.880
Acinetobacter spp. 6 6.7 52 14.8 0.042 *
Salmonella 44 . 41 2 3 . 4 0 . 7 5 1 #
Citrobacter spp. 3 3.3 6 1.7 0.396 #
Proteus spp. 3 3.3 1 0.3 0.028 #*
Aeromonas spp. 1 1.1 8 2.3 0.693 #
Stenotrophomonas maltophilia 0 0.0 7 2.0 0.353 #
Achromobacter spp 0 0.0 1 0.3 0.999 #
Alcaligenes xylosoxidans 1 1.1 0 0.0 0.204 #
Chryseomonas luteola 0 0.0 1 0.3 0.999 #
Campylobacter spp. 0 0.0 1 0.3 0.999 #
p-values calculated by Chi square test otherwise indicated
# p-value calculated by Fisher exact test
* p < 0.05BMC Infectious Diseases 2008, 8:80 http://www.biomedcentral.com/1471-2334/8/80
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Table 4: Difference in sensitivity pattern of frequently isolated Gram positive bacteria during two halves of study period.
Staphylococcus species other than 
aureus
Staphylococcus aureus Enterococcus species
Period 1 Period II Period 1 Period II Period 1 Period II
n = 56 % n = 250 % p-value n = 14 % n = 43 % p-value n = 7 % n = 23 % p-value
Vancom
ycin
0 0 0 0 - 0000 - 0 03 1 3 . 0 0 . 9 9 9   #
Cloxacill
in
30 53.6 130 52.0 0.831 3 21.4 13 30.2 0.735 # NT - NT - -
Penicillin 49 87.5 192 76.8 0.077 12 85.7 40 93.0 0.587 # NT - NT - -
Clindam
ycin
20 35.7 82 32.8 0.676 3 21.4 13 30.2 0.735 # NT - NT - -
Ampicilli
n
NT - NT - - NT - - NT - 7 100 17 73.9 0.290 #
p-values calculated by Chi square test otherwise indicated
# p-value calculated by Fisher exact test
Table 3: Difference in sensitivity pattern of frequently isolated Gram negative rods during two halves of study period.
(a)
Enterobacteriaceae Pseudomonas. aeruginosa
Period 1 Period II Period I Period II
n = 55 % n = 212 % P-value n = 15 % n = 34 % P-value
Amikacin 6 10.9 35 16.5 0.305 0 0 4 11.8 0.298 #
Amox/clav 25 45.5 102 48.1 0.725 NT NT NT NT -
Ceftriaxone 13 23.6 118 55.7 < 0001* NT NT NT NT -
Ciprofloxacin 15 27.3 105 49.5 0.003 * 2 13.3 10 29.4 0.298 #
Tazocin 0 0 24 11.3 0.006 * 0 0 4 11.8 0.298 #
I m i p e n e m 00 0 0 - 002 5 . 9 0 . 9 9 9   #
Ceftazidime NT NT NT NT - 1 6.7 2 5.9 0.999 #
(b)
Pseudomonas species Acinetobactor
Period 1 Period II Period 1 Period II
n = 8 % n = 29 % p-value n = 6 % n = 52 % p-value
Amikacin 4 50.0 12 41.4 0.705 # 1 16.7 27 51.9 0.195 #
Amox/clavilunate NT NT NT NT - NT NT NT NT -
Ceftriaxone 0 0 7 24.1 0.308 # 0 0 39 75.0 0.001 #*
Ciprofloxacin 1 12.5 7 24.1 0.655 # 0 0 33 63.5 0.004 #*
Pipracillin/Tazobactam 0 0 2 6.9 0.999 # 0 0 34 65.4 0.003 #*
Imipenem 0 0 6 20.7 0.305 # 0 0 34 65.4 0.003 #*
Ceftazidime NT NT NT NT - NT NT NT NT -
p-values calculated by Chi square test otherwise indicated
# p-value calculated by Fisher exact test
* p < 0.05BMC Infectious Diseases 2008, 8:80 http://www.biomedcentral.com/1471-2334/8/80
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mised infection control practice is another contributing
factor, hence early detection and prompt isolation of
patients with strict compliance to hand hygiene is impor-
tant to prevent further spread of multi resistant organisms.
Conclusion
This rising trend of highly resistant organisms stresses the
increasing importance of continuous surveillance system
and stewardship of antibiotics as strategies in the overall
management of patients with febrile neutropenia.
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